Clinical Trial Update: A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating low-dose decitabine in relapsed or refractory acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Dacogen (decitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Lymphocytic Leukemia | Phase 1 | Status: COMPLETED